
Active Biotech Q4 2022 - Laquinimod Ready for Phase II

Redeye comments on Active Biotech's report for the fourth quarter and discusses events and the status of the clinical programs.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Active Biotech Q4 2022 - Laquinimod Ready for Phase II